BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline

Reuters

Dec 01

Dec 1 (Reuters) - Akebia Therapeutics Inc AKBA.O:

AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINE
AKEBIA THERAPEUTICS: ACQUIRES NEXT GENERATION TISSUE-TARGETED C3D-FACTOR H FUSION PROTEIN COMPLEMENT INHIBITOR FROM Q32 BIO
AKEBIA THERAPEUTICS: PHASE 2 BASKET TRIAL PLANNED TO EVALUATE COMPLEMENT INHIBITOR IN MULTIPLE RARE KIDNEY DISEASE INDICATIONS
AKEBIA THERAPEUTICS INC: PHASE 2 TRIAL OF PRALICIGUAT INITIATED IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS $(FSGS)$
AKEBIA THERAPEUTICS INC: BOTH TRIALS PLANNED TO START TREATING SUBJECTS IN 2026

Source text: ID:nGNXbsqDF1

Further company coverage: AKBA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2588819778"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588819778\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588819778?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588819778","market":"us","top_or_hot":-1,"title":"BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline</title></head><body><p><span>Dec 1 (Reuters)</span><span> - </span>Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>AKBA.O</span>:</p><ul><li><p>AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINE</p></li><li><p>AKEBIA THERAPEUTICS: ACQUIRES NEXT GENERATION TISSUE-TARGETED C3D-FACTOR H FUSION PROTEIN COMPLEMENT INHIBITOR FROM Q32 BIO</p></li><li><p>AKEBIA THERAPEUTICS: PHASE 2 BASKET TRIAL PLANNED TO EVALUATE COMPLEMENT INHIBITOR IN MULTIPLE RARE KIDNEY DISEASE INDICATIONS</p></li><li><p>AKEBIA THERAPEUTICS INC: PHASE 2 TRIAL OF PRALICIGUAT INITIATED IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS <a href=\"https://laohu8.com/S/FSGS\">$(FSGS)$</a></p></li><li><p>AKEBIA THERAPEUTICS INC: BOTH TRIALS PLANNED TO START TREATING SUBJECTS IN 2026</p></li></ul><p>Source text: <span>ID:nGNXbsqDF1</span></p><p>Further company coverage: <span>AKBA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-01 21:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline</title></head><body><p><span>Dec 1 (Reuters)</span><span> - </span>Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>AKBA.O</span>:</p><ul><li><p>AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINE</p></li><li><p>AKEBIA THERAPEUTICS: ACQUIRES NEXT GENERATION TISSUE-TARGETED C3D-FACTOR H FUSION PROTEIN COMPLEMENT INHIBITOR FROM Q32 BIO</p></li><li><p>AKEBIA THERAPEUTICS: PHASE 2 BASKET TRIAL PLANNED TO EVALUATE COMPLEMENT INHIBITOR IN MULTIPLE RARE KIDNEY DISEASE INDICATIONS</p></li><li><p>AKEBIA THERAPEUTICS INC: PHASE 2 TRIAL OF PRALICIGUAT INITIATED IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS <a href=\"https://laohu8.com/S/FSGS\">$(FSGS)$</a></p></li><li><p>AKEBIA THERAPEUTICS INC: BOTH TRIALS PLANNED TO START TREATING SUBJECTS IN 2026</p></li></ul><p>Source text: <span>ID:nGNXbsqDF1</span></p><p>Further company coverage: <span>AKBA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKBA","symbol_name":"Akebia Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:1","article_id":"2588819778","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588819778","pubTimestamp":1764595262,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Akebia Announces Establishment Of Rare Kidney Disease PipelineDec 1 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINEAKEBIA THERAPEUTICS: ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKBA":"Akebia Therapeutics, Inc.","BK4139":"生物科技","QTTB":"Q32 Bio Inc."},"translate_title":"BRIEF-Akebia宣布建立罕见肾病管道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTTB":0.9,"AKBA":0.9},"content_text":"BRIEF-Akebia Announces Establishment Of Rare Kidney Disease PipelineDec 1 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINEAKEBIA THERAPEUTICS: ACQUIRES NEXT GENERATION TISSUE-TARGETED C3D-FACTOR H FUSION PROTEIN COMPLEMENT INHIBITOR FROM Q32 BIOAKEBIA THERAPEUTICS: PHASE 2 BASKET TRIAL PLANNED TO EVALUATE COMPLEMENT INHIBITOR IN MULTIPLE RARE KIDNEY DISEASE INDICATIONSAKEBIA THERAPEUTICS INC: PHASE 2 TRIAL OF PRALICIGUAT INITIATED IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS $(FSGS)$AKEBIA THERAPEUTICS INC: BOTH TRIALS PLANNED TO START TREATING SUBJECTS IN 2026Source text: ID:nGNXbsqDF1Further company coverage: AKBA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}